Recently, an article by Rex Graham was published on SanDiegoBiotechnology.com discussing Cardium Therapeutics (NYSE MKT: CXM).
An excerpt from the article:
"While tiny startups making smartphone apps can turn hot ideas into sizzling million-dollar success stories overnight, Cardium Therapeutics (NYSE MKT: CXM) has been patiently moving forward with a promising gene therapy for more than a decade. The San Diego-based company is developing Generx, a gene therapy treatment to boost the growth of blood vessels in the hearts of patients suffering from coronary artery disease. Cardium advanced Generx with the start of an international Phase 3 registration study based on new important research findings.
Federal approval of any new drug can take decades of scientific and clinical research and more than $1 billion to develop. Even then, there is no sure thing: only one in 10 drug candidates makes it to market. However, Cardium researchers are convinced that a decade of fine-tuning Generx, which is designed to stimulate the heart’s natural healing process, will successfully induce the growth of small blood vessels in the heart, thereby avoiding the need for surgery to improve cardiac blood flow.
The human heart, when injured, has the ability to grow small blood vessels, commonly referred to as “collateral circulation.” Generx is designed to boost that collateral circulation with a replication-deficient adenovirus vector type 5 that carries a gene for human fibroblast growth factor 4 (Ad5FGF-4). It is delivered inexpensively to the heart with a standard catheter to leverage a process called “angiogenesis,” the natural growth of small blood vessels."
Read the complete article at: http://sandiegobiotechnology.com/topics/4705/cardiums-heart-disease-gene...
Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated two thousand five hundred dollars by Cardium Therapeutics for its efforts in managing the dissemination of public corporate information on its website and to its database of subscribers and across select financial and social media websites. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.